Image de couverture de livre

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Jonggi Choi
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
par: Kanghee Park, et autres
Publié: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
par: Daniel Q. Huang, et autres
Publié: (2026)

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
par: Najib Ben Khaled, et autres
Publié: (2025)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
par: Hyeyeon Hong, et autres
Publié: (2024)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
par: Subin Heo, et autres
Publié: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
par: Jiwon Yang, et autres
Publié: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
par: Shuaibing Ying, et autres
Publié: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
par: Lesley A. Patmore, et autres
Publié: (2025)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
par: Sung Won Chung, et autres
Publié: (2024)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
par: Gamal Shiha, et autres
Publié: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
par: Elisa Pinto, et autres
Publié: (2026)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
par: Kuo‐Cheng Wu, et autres
Publié: (2024)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
par: Min Joo Yoon, et autres
Publié: (2026)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
par: Vincent Haghnejad, et autres
Publié: (2025)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
par: Jiong Yu, et autres
Publié: (2024)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
par: Nikolaj Torp, et autres
Publié: (2025)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
par: Michelle Spaan, et autres
Publié: (2026)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC. Authors' Reply
par: Natassia Tan, et autres
Publié: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
par: L. Aceituno, et autres
Publié: (2026)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
par: Nauzer Forbes, et autres
Publié: (2024)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
par: Ramin Ebrahimi, et autres
Publié: (2025)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
par: Subin Heo, et autres
Publié: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
par: Lichao Qiao, et autres
Publié: (2025)

Editorial: Disorders of gut‐brain interaction—Don't forget the older person
par: Christopher J. Black
Publié: (2024)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
par: Kaitlyn Carlson, et autres
Publié: (2026)

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply
par: Zahra Sarrafan‐Chaharsoughi, et autres
Publié: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
par: Máté Szilcz, et autres
Publié: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
par: Jeongkuk Seo, et autres
Publié: (2024)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
par: Yu‐Ping Chang, et autres
Publié: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
par: Virginia Solitano, et autres
Publié: (2024)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’. Authors' Reply
par: Hermann Brenner, et autres
Publié: (2025)

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
par: Daniel Q. Huang, et autres
Publié: (2026)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
par: Silvia Nardelli, et autres
Publié: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
par: Yi Xiang, et autres
Publié: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
par: A. B. Fons, et autres
Publié: (2026)